Shulman Rogers was pleased to advise our client, Veralox, in their $5.4M capital raise. A biotechnology company based in Frederick, Maryland, Veralox will use the funding to advance the development of first-in-class therapeutics to address unmet medical needs. We were thrilled to play a role in this transaction and very much look forward to their continued growth and success.
For more information and to access the full press release: https://bwnews.pr/2k9XNpM
Stay up to date with all the latest news and events.